 Based on the preset criteria, the IDMC recommended that the trial continue. FRUTIGA is a Phase III trial in China of fruquintinib in combination with paclitaxel Taxol in the treatment of patients with advanced gastric adenocarcinoma or gastroesophageal junction GEJ adenocarcinoma who have progressed after first-line standard chemotherapy. 